The Bull Market for Radiology Drugs and Developing a North American Supply

Voyageur Pharmaceuticals (TSXV:VM) (OTC:VYYRF) is focused on vertically integrating the barium, iodine and carbon contrast imaging market – think radiology drugs and medical imaging. [Open in your browser]( [Stockhouse.com]( [Investor Alert] [The Bull Market for Radiology Drugs and Developing a North American Supply ] Progress for Radiology Drugs and Medical Imaging Company --------------------------------------------------------------- [Visit the company website]( [Facebook]( [Twitter]( for Radiology Drugs and Medical Imaging Company) [LinkedIn]( [Email](mailto:?subject=Progress for Radiology Drugs and Medical Imaging Company&body= The Top Line | CEO Interview Voyageur Pharmaceuticals ([TSXV:VM]( ([OTC:VYYRF]( is focused on vertically integrating the barium, iodine and carbon contrast imaging market – think radiology drugs and medical imaging. Its business plan is set to generate immediate cash flow by partnering with third party GMP pharmaceutical manufacturers in Canada before transitioning to being a high margin manufacturer of radiology drugs. [SEE COMPANY PROFILE]( Click to view Minor changes have been made to the transcript for additional clarity. TMH | Brent, let's start by focusing on the barium side of the business, which is unusual for a pharmaceutical company. The company has its own natural source of barite. Can you let investors know where this project stands? Brent Willis | We've been advancing the project. We've identified a resource of one of the highest-grade barium sulfate deposits to be discovered. And the next phase is applying for our notice of work to do a 1,000 to 2,000 tonne sample so that we have the material ready for when our pharmaceutical plant is completed and ready for production. At the same time we're taking the data that we're collecting out in the field, and we're going to be using that to apply for our quarry permit, where we're working on getting the Francis Creek Project permitted in 2024 for quarry operations. TMH | Can you expand a little bit on what is contrast imaging and what makes it so valuable to the company? Brent Willis: Contrast imaging is used in radiology. People go in for scans for X-ray, CTs, MRIs and we develop the products used to help differentiate between the tissues in the body and a disease that may exist within the body. So it's a diagnostic tool. And the drugs we make is for diagnosing disease, which is very important in this day and age. TMH | More recently you announced a deal with Rain Cage Carbon to develop fullerene. For investors who don't know, what is fullerene and how can it help in the medical imaging market? Brent Willis | Fullerene are carbon allotropes consisting of carbon 20 to carbon 120, and we're focused on taking these fullerenes and creating new drugs with them. It's been proven at the lab scale that there's an application where you can potentially use it as drug delivery. And in the radiology business, we are looking at using it to deliver iodine, gadolinium and safely move those products around the body and increase the efficiency of those scans to help detect disease earlier. It is very ground breaking technology. [INVESTOR UPDATES]( TMH | What has the progress of the company been for the last two to three years and why should investors invest now? Brent Willis | We've made a lot of inroads. We have a resource ready to go into the production phase. We have five products that are Health Canada approved. We are working with the FDA, we're working to get FDA approval on our products in 2024for all our products. And we're competing in a growing market that we are vertically integrating, which allows for low cost production of our products. it's a very exciting time for Voyageur and for investors to join us on this journey. TMH | Looking at both, the North American and the wider global markets in the medium and long term, what patterns do you see developing, and where does Voyageur fit in? Brent Willis | We're seeing an increase in inflammatory disease and that trend  has been increasing in the last few years at a higher rate than we have seen in the past. We have GE Healthcare who have stated that they expect the market for iodine contrast to double in the next 10 years. And that's just a reflection on the high demand in our western world that requires these drugs to diagnose disease. There are currently serious shortages of these drugs which is pushing prices higher. So we're in a bull market in radiology imaging drugs. And it's going to continue. It's a very, very exciting time for Voyageur and for Voyageur investors. Learn more about Voyageur at [voyageurpharmaceuticals.ca.]( [VIEW COMPANY WEBSITE]( This is sponsored content issued on behalf of Voyageur Pharmaceuticals, please see the full disclaimer [here](. The Information in a Stockhouse Publishing Ltd. Stockhouse Alert is a paid advertisement and is for the viewers information only. The corporate information is purely and solely the responsibility of Voyageur Pharmaceuticals Ltd and it is neither commented upon, researched, or in any manner the responsibility of Stockhouse Publishing Ltd., whose only function is as a supplier of media facilities. Any information provided by the advertisers of Stockhouse Publishing Ltd., through its media services, is not to be construed as a recommendation or suggestion or offer to buy or sell securities but is provided purely as an informational media service. Stockhouse Publishing Ltd. makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the reader or their financial advisor. Investing in securities is speculative and carries risk. Persons who wish to buy or sell securities should only do so at their own risk and in consultation with their registered securities advisers. --------------------------------------------------------------- [stockhouse]( Stockhouse Publishing Ltd. 1100 – 609 West Hastings Street | Vancouver | BC | V6B 4W4 | CA [Unsubscribe]( | [Manage Preferences]( [Facebook]( [Twitter]( [LinkedIn]( This email was sent to you by Stockhouse Publishing Ltd. because you consented to receive messages from us. You may manage your subscription preferences at any time. You may contact our email compliance officer at compliance@stockhouse.com